Retatrutide Skin Sensitivity: The Short Version

Dysesthesia is an altered sense of touch: skin that feels sensitive, tingles or burns, or ordinary contact that feels unpleasant or painful. It was reported more often than on placebo in all five retatrutide Phase 3 trials with results so far — at the highest dose, 12 mg, in 4.4% to 20.9% of participants, depending on the trial.

Lilly describes the events as generally mild, or mild to moderate, and for four of the five trials said the majority resolved during treatment. Neither its announcements nor the TRIUMPH-1 paper, published in full in September 2026, say how long individual episodes lasted.

It is not unique to retatrutide. Semaglutide's US label lists it at up to 22% on the highest dose, and tirzepatide's at up to 0.4%. Why these drugs cause it has not been established. The other side effects reported in the trials are covered in retatrutide side effects.

What Dysesthesia Feels Like

Cleveland Clinic defines dysesthesia as symptoms that disrupt how a person experiences touch-based sensations, which can feel unpleasant, unusual or painful. People describe it as burning, tingling, pins and needles, crawling, prickling, itching, or feeling unusually cold or warm. Reports of feeling hot on retatrutide are a separate question, covered in retatrutide and body temperature.

Two related terms often appear alongside it. Paresthesia, the pins-and-needles feeling of a limb that has fallen asleep, is one type of dysesthesia. Allodynia is pain from something that should not hurt, such as clothing or water on the skin; dysesthesia does not have to be painful, but allodynia always is.

Trials group these sensations differently. Semaglutide's label counts paresthesia, burning sensation, pain of skin, sensitive skin and similar terms together, and retatrutide's Phase 2 obesity trial reported "cutaneous hyperesthesia and skin sensitivity." The Phase 3 announcements use the single word dysesthesia without saying which terms it includes, and the published TRIUMPH-1 paper labels the category "dysesthesia: skin burning sensation and related adverse events."

How Common Was Skin Sensitivity in Retatrutide's Trials?

The TRIUMPH-1 figures come from the paper published in the New England Journal of Medicine in September 2026, and the others from Lilly's announcements; TRIUMPH-2 and TRANSCEND-T2D-1, both in type 2 diabetes, have also been published in full in The Lancet.

The rate rose with the dose in TRIUMPH-2 and TRIUMPH-4 — in TRIUMPH-4 it more than doubled from 9 mg to 12 mg — and in TRIUMPH-1 from 4 mg to 9 mg, with little change from 9 mg to 12 mg. It did not in TRIUMPH-3, where both doses had 6.4%, or in TRANSCEND-T2D-1, where 9 mg had the lowest rate. The highest figure, 20.9%, came from TRIUMPH-4, a trial in people with knee osteoarthritis; the company's announcements do not explain why it was higher there.

It was not entirely new. In the 48-week Phase 2 obesity trial, published in 2023, cutaneous hyperesthesia and skin sensitivity were reported in 7% of participants on retatrutide and 1% on placebo — 13% on the 12 mg dose. None of those events were severe or serious, none came with visible skin changes, and none led anyone to stop treatment.

How Long Does Retatrutide Skin Sensitivity Last?

For retatrutide itself, the answer so far is general, and most of the company's statements cover dysesthesia and urinary tract infections together. For TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 and TRANSCEND-T2D-1, it said those events were generally mild to moderate and that the majority resolved during treatment, adding for TRIUMPH-1 and TRANSCEND-T2D-1 that most participants continued taking retatrutide; its March 2026 announcement of TRANSCEND-T2D-1 had described the dysesthesia events alone as generally mild, with a majority resolving during treatment. For TRIUMPH-4, it said they were generally mild and rarely led to discontinuation. The published TRIUMPH-1 paper describes dysesthesia, together with injection-site reactions and low blood pressure, as mostly mild or moderate and nonserious. But neither the announcements nor the paper give how long the events took to resolve, how many people still had symptoms when the trial ended, or what happened after treatment stopped.

Semaglutide's label gives a more detailed picture of how this side effect has behaved in a related drug — though it describes semaglutide at 7.2 mg, not retatrutide. Of 288 people who had dysesthesia on that dose, 18% had not reported recovering by the end of the 72-week trials, so most did. Only 2% stopped treatment permanently; 8% paused it and 23% had their dose reduced, and of 38 who recovered and later went back up to 7.2 mg, 17 had it again. Those were decisions made by trial investigators for a different drug, and the label reports them as observations, not as a tested way to manage the side effect.

Reports from outside the retatrutide trials point the same way. New Zealand's medicines regulator noted that in semaglutide's trials most patients recovered while continuing treatment. A 2026 study of pharmacovigilance reports for GLP-1-based medicines found that, in the French cases it reviewed, symptoms began between 3 and 93 days after the first injection; where treatment was stopped, symptoms resolved on their own, and in the three people who restarted at the same dose, they came back.

Is Dysesthesia Unique to Retatrutide?

No. Semaglutide and tirzepatide list it on their US labels too. How the three drugs compare more broadly is covered in retatrutide vs tirzepatide vs semaglutide.

These figures come from different trials, of different lengths and populations, and the sources may not count the same sensations: semaglutide's include related terms such as paresthesia and burning, while tirzepatide's label and Lilly's retatrutide announcements do not say which terms they include, and the TRIUMPH-1 paper describes its category only as skin burning sensation and related events. With that caveat, retatrutide's rates are higher than those tirzepatide's label reports, and at 12 mg in TRIUMPH-1 its rate was above semaglutide 2.4 mg's on either measure and below semaglutide 7.2 mg's.

Regulators have taken note of the class. In March 2026, New Zealand's medicines regulator advised health professionals to consider GLP-1 medicines as a possible cause when patients present with altered skin sensations, and in April 2026 UK product information for two semaglutide diabetes products was updated to list dysaesthesia. A 2026 analysis of VigiBase, the WHO's global database of spontaneous adverse-event reports, found that dysesthesia and burning sensations were reported disproportionately often with semaglutide, and hyperesthesia with both semaglutide and tirzepatide.

Why Does Retatrutide Cause Skin Sensitivity?

The cause has not been established, and neither the company's announcements nor the published TRIUMPH-1 paper offer one. The authors of the 2026 pharmacovigilance study list several hypotheses for the class — loss of fat under the skin, nutritional deficiencies, indirect metabolic or vascular effects on nerves, and direct effects on sensory nerves, which carry GLP-1 and GIP receptors — while noting that the mechanism remains unknown.

The glucagon receptor, retatrutide's third target, is not needed to produce it: semaglutide acts on the GLP-1 receptor alone, and its label lists the same side effect. Whether the glucagon receptor adds to retatrutide's rate is not known.

Whether weight loss plays a part is not settled. In retatrutide's Phase 2 trial, the investigators reported that these events did not appear to be related to the magnitude or rate of weight loss. The authors of the pharmacovigilance study noted that the increase in dysesthesia with semaglutide 7.2 mg occurred shortly after the step up from 2.4 mg, which they took as a sign that it is unlikely to be caused by weight or fat loss. Semaglutide's label reports, and that study concluded, that the effect is more common at higher doses — a pattern seen in some but not all of retatrutide's trials.

Is It Nerve Damage?

Lilly's announcements and the Phase 2 publication do not describe it that way. The company describes the events as generally mild, or mild to moderate, and for four of the five reported Phase 3 trials said the majority resolved during treatment; in Phase 2 none were severe and none came with visible skin changes. The TRIUMPH-1 paper describes the events as mostly mild or moderate and nonserious. The long-term course is less clear: neither the announcements nor the paper give durations or say what happened after people stopped.

Dysesthesia also has many possible causes besides medication — Cleveland Clinic lists nervous system, metabolic and autoimmune conditions, infections and toxic exposures among them — which is one reason a persistent altered sense of touch cannot be put down to a drug by default.

Why This Page Has No Treatment Advice

Many searches about this side effect are looking for a fix, and some articles offer one: creams, supplements, nerve-pain medicines, or cutting the dose. This page does not, deliberately. Retatrutide has no approved dose or label, so there is no approved way to adjust it, and in the trials these decisions were made by the investigators running them. What semaglutide's label reports about dose changes describes supervised trials of a different drug.

Products sold online under the retatrutide name are not sold or supplied by Lilly. The company says retatrutide is legally available only through its clinical trials; in August 2026 it said it would also make it available to a limited number of patients who meet specific medical criteria and cannot enroll in a trial. It warns that illicit products "may contain unknown ingredients, harmful contaminants and impurities," so symptoms after taking one of them cannot be assumed to be the dysesthesia seen in the trials.

What Comes Next

TRIUMPH-1 was published in full in the New England Journal of Medicine in September 2026, and TRIUMPH-2 was presented at the EASD meeting in Milan and published in The Lancet the same month. The company's announcement of the TRIUMPH-2 results gives the same dysesthesia rates as its July topline report, 7.3% on 12 mg against 0.7% on placebo, and again says the events were generally mild to moderate, with the majority resolving during treatment. Neither it nor the TRIUMPH-1 paper reports how long dysesthesia lasted or what happened after treatment stopped. We will update this page when more detailed data appear.

Retatrutide Dysesthesia in Summary

Dysesthesia — skin sensitivity, tingling or burning — was reported in every retatrutide Phase 3 trial with results so far, at 12 mg in 4.4% to 20.9% of participants. The company describes it as generally mild to moderate and mostly resolving during treatment, but neither its announcements nor the published TRIUMPH-1 paper say how long it lasts. Its rates are higher than those tirzepatide's label reports, though the figures come from different trials and may not count the same symptoms, and it is shared with semaglutide, whose label lists it at up to 22%. Its cause has not been established.

Sources

• Eli Lilly. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025.
• Eli Lilly. Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. March 19, 2026.
• Eli Lilly. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026.
• Eli Lilly. Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications. June 6, 2026.
• Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
• Eli Lilly. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. September 29, 2026.
• Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
• Lilly Medical. What is the impact of retatrutide in patients with obesity or overweight and osteoarthritis of the knee? Last reviewed August 31, 2026.
• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526.
• Novo Nordisk. Wegovy (semaglutide) US prescribing information, section 6.1. Revised June 2026.
• Eli Lilly. US prescribing information for tirzepatide for weight reduction, section 6.1. Revised August 2026.
• Medsafe (New Zealand Medicines and Medical Devices Safety Authority). GLP-1 receptor agonists and altered skin sensations. Prescriber Update 47(1), March 2026.
• Laroche M-L, Géniaux H, Jardou M. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. Eur J Clin Pharmacol. 2026;82:154.
• The Pharmaceutical Journal. Dysaesthesia added to semaglutide side effects list. April 9, 2026.
• Cleveland Clinic. Dysesthesia. Health Library.
• Eli Lilly. What to know about retatrutide. Last updated September 2026.
• STAT. Eli Lilly to allow more patients to apply for special access to unapproved obesity drug. August 3, 2026.

Medical Disclaimer: This article is for informational purposes only and is not medical advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and products sold online under its name are not sold or supplied by Lilly.